SecBot SecBot
SECBOTREPLAY Home › Report › VERA

VERA · Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all…

Vera Therapeutics, Inc. · 8-K filed Sep 15, 2026 at 06:45 ET

At the news

BULLISHIMPACT 8/10

8-K filed Sep 15, 2026 at 06:45 ET

Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 Phase 3 trial in IgA nephropathy (IgAN). The drug demonstrated a 5.6 mL/min/1.73m2 placebo-adjusted difference in mean eGFR change at 52 weeks (p<0.0001), a 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, p<0.0001), and a favorable safety profile. The company plans to submit a supplemental BLA for full approval in Q4 2026, and reported strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. This is a transformative data readout that strongly supports the drug's disease-modifying potential and de-risks the path to full approval, representing a major positive catalyst for the stock.

  • TRUTAKNA met all prespecified endpoints in the ORIGIN 3 final efficacy analysis (n=428).
  • Placebo-adjusted difference in mean eGFR change from baseline at 52 weeks was 5.6 mL/min/1.73m2 (p<0.0001).
  • Annualized eGFR slope through 104 weeks showed a placebo-adjusted difference of 5.0 mL/min/1.73m2/year (p<0.0001).
  • 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, 95% CI 0.12-0.48, p<0.0001).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access